Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 11, 2022 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19

BOTHELL, Wash., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the selection of its novel, broad-spectrum antiviral drug candidate CDI-988 for clinical development...